Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. is a US-based biotechnology company focused on developing engineered therapeutics using drug-responsive domains to create controlled therapies for oncology and autoimmune diseases. Founded in 2015 and headquartered in Cambridge, US, Obsidian Therapeutics specializes in engineered therapeutics. The company has undergone strategic pivots and raised a total of USD 160.

50 mn, primarily through its latest funding round, Series C, led by Wellington Management on April 3, 2024. The company's leadership includes CEOs Madan Jagasia and Paul Wotton. Obsidian Therapeutics is at the forefront of engineered therapeutics, primarily offering innovative solutions that leverage drug-responsive domains (DRDs) to modulate protein function. The company’s flagship product, OBX-115, is currently under investigation and is part of their proprietary cytoDRIVE® platform, which aims to deliver precision cell and gene therapies.

These products address critical therapeutic needs in areas such as oncology and autoimmune diseases, where precise control over protein activity can significantly enhance treatment efficacy. The customer base primarily consists of pharmaceutical partners, research institutions, and healthcare providers operating in North America, Europe, and Asia, who are focused on advancing treatment options for patients with complex health conditions. The ongoing development and testing of these products underscore Obsidian's commitment to improving patient outcomes through innovative therapeutic strategies. Obsidian Therapeutics generates revenue through structured partnerships and collaborations in the biopharmaceutical space.

The company engages in joint ventures with pharmaceutical firms and research institutions, focusing on the advancement of their investigational products. Revenue streams are facilitated through milestone payments associated with clinical trial progress and potential licensing agreements for their proprietary technologies, including OBX-115 and the cytoDRIVE® platform. As a biotechnology firm, Obsidian enters agreements involving upfront fees and ongoing royalties based on product sales, reflecting a B2B model where the primary clients are larger pharmaceutical companies seeking to enhance their therapeutic portfolios. These strategic partnerships align with the rigorous requirements of drug development, ultimately leading to the commercialization of their innovative offerings.

In April 2024, Obsidian Therapeutics, Inc. raised USD 160. 50 mn in Series C funding to advance its lead-engineered program. The company plans to utilize this capital for the further development and potential launch of its products, including OBX-115, targeting critical therapeutic areas.

Additionally, Obsidian is looking to expand its reach into new markets, specifically in Europe and Asia, with plans to initiate this expansion by 2025. The funding will support initiatives aimed at enhancing research capabilities and accelerating clinical trials.